Literature DB >> 15800995

Traditional Chinese medicine syndromes of chronic hepatitis B with precore mutant.

Hong-Zhi Yang1, Jian-An Zhao, Min Dai, Yong-Wei Li, Yong-Ze Wang, Wei-Bing Guan, He-Ping Xie.   

Abstract

AIM: This study aims at exploring the distribution of TCM syndromes in CHB patients with HBV pre-core mutation (1896) and the relationship between pre-core mutation and T lymphocytes subgroup, through which to provide objective data on clinical syndrome differentiation of TCM, and further to suggest the therapeutic principle and guide clinical treatment.
METHODS: One hundred and forty CHB patients were evenly divided into two study groups, HBV pre-core mutant group and HBV pre-core wild-type group. Besides, 30 healthy blood donors were selected as a healthy control group. HBV-labeled compound, T lymphocytes subgroup, and HBV-DNA pre-core mutant were tested in the study groups. T lymphocytes subgroup were also tested in the control group. All the patients were both diagnosed by syndrome differentiation of TCM and western medicine.
RESULTS: The most common syndrome in mutant group was damp-heat combined with blood stasis, and the most common syndrome in the wild-type group was damp-heat stasis in the middle-jiao. There were more cases of medium and severe hepatitis in mutant group than that in wild-type group. The content of CD4+ lymphocytes and CD4+/CD8+ ratio were decreased gradually (healthy control group>wild-type group>mutant group). In the wild-type group, severe and medium CHB patients had considerably lower level of them than mild CHB patients. However, in the mutant group, the opposite result appeared. Meanwhile, the content of HBV-DNA in mutant group was higher than that in wild-type group.
CONCLUSION: Damp, heat, toxin and blood stasis were the basic pathogens of CHB, whether pre-core mutant or not. CHB with precore mutant may lead to more severe hepatitis. The decreased content of CD4+ lymphocytes and ratio of CD4+/CD8+ may be taken as one of the indices in confirming the deficiency syndrome of CHB patients with pre-core mutation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15800995      PMCID: PMC4305726          DOI: 10.3748/wjg.v11.i13.2004

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  19 in total

1.  [Improved APAAP immunocytochemical staining-trace cytotoxicity test plate method for detection of cell surface antigens].

Authors:  H Jiang; M Cai
Journal:  Hua Xi Yi Ke Da Xue Xue Bao       Date:  2001-03

2.  Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab.

Authors:  José-Angel Hernández; Raúl Diloy; David Salat; Neus del Río; Xavier Martínez; Josep-María Castellví
Journal:  Haematologica       Date:  2003-06       Impact factor: 9.941

3.  Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role.

Authors:  J L Steinberg; W Yeo; S Zhong; J Y Chan; J S Tam; P K Chan; N W Leung; P J Johnson
Journal:  J Med Virol       Date:  2000-03       Impact factor: 2.327

4.  Reactivation of precore mutant hepatitis B virus in chemotherapy-treated patients.

Authors:  M S Dai; J J Lu; Y C Chen; C L Perng; T Y Chao
Journal:  Cancer       Date:  2001-12-01       Impact factor: 6.860

5.  Vertical transmission of hepatitis B virus despite maternal lamivudine therapy.

Authors:  Syed N Kazim; Salma M Wakil; Luqman A Khan; Seyed E Hasnain; Shiv K Sarin
Journal:  Lancet       Date:  2002-04-27       Impact factor: 79.321

6.  Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient.

Authors:  S Ito; K Nakazono; A Murasawa; Y Mita; K Hata; N Saito; M Kikuchi; K Yoshida; M Nakano; F Gejyo
Journal:  Arthritis Rheum       Date:  2001-02

7.  Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma.

Authors:  S Kubo; K Hirohashi; H Tanaka; T Tsukamoto; T Shuto; T Yamamoto; T Ikebe; K Wakasa; S Nishiguchi; H Kinoshita
Journal:  Cancer       Date:  2000-03-01       Impact factor: 6.860

8.  Abnormal immunity and gene mutation in patients with severe hepatitis-B.

Authors:  Jing-Yan Wang; Pei Liu
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

9.  Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a.

Authors:  Ingolf Schiefke; Chris Klecker; Melanie Maier; Ute Oesen; Gunnar Etzrodt; Andrea Tannapfel; Uwe G Liebert; Frieder Berr
Journal:  Liver Int       Date:  2004-04       Impact factor: 5.828

10.  Response to interferon-alpha in chronic hepatitis B with and without precore mutant strain detected by mutation site-specific assay.

Authors:  Yasushi Seo; Seitetsu Yoon; Kenichi Hamano; Miyuki Nakaji; Yoshihiko Yano; Megumi Katayama; Toshiaki Ninomiya; Yoshitake Hayashi; Masato Kasuga
Journal:  J Clin Gastroenterol       Date:  2004 May-Jun       Impact factor: 3.062

View more
  3 in total

1.  Chinese medicine syndrome distribution of chronic hepatitis B virus carriers in immunotolerant phase.

Authors:  He-ping Xie; Hong-zhi Yang; Wei-kang Wu; Wei-bing Guan; Qian-shan Ke; Yong-wei Li; Min Dai; Ge-min Xiao; Jiong-shan Zhang; Yang-mei Li
Journal:  Chin J Integr Med       Date:  2014-03-06       Impact factor: 1.978

2.  iTRAQ-Based Proteomics Identification of Serum Biomarkers of Two Chronic Hepatitis B Subtypes Diagnosed by Traditional Chinese Medicine.

Authors:  Jiankun Yang; Lichao Yang; Baixue Li; Weilong Zhou; Sen Zhong; Zhenhua Zhuang; Bin Yang; Maoshan Chen; Quansheng Feng
Journal:  Biomed Res Int       Date:  2016-11-29       Impact factor: 3.411

3.  Traditional Chinese Medicine Syndrome Patterns and Their Association with Hepatitis B Surface Antigen Levels during the Natural History of Chronic Hepatitis B Virus Infection.

Authors:  He-Ping Xie; Zhi-Ping Liu; Jiong-Shan Zhang; Min Dai; Ge-Min Xiao; Wei-Kang Wu; Hong-Zhi Yang
Journal:  Evid Based Complement Alternat Med       Date:  2018-10-02       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.